High throughput screening assay for the TRPM5 ion channel
View Patent ↗There exists a need in the art for high throughput screening assays that can identify compounds that specifically modulate the activity of fast-acting ion channels, such as TRPM5. Current methods suffer from a lack of sensitivity, low throughput, and are labor intensive. The claimed methods provide fluorescent assays with an optical readout that gives rapid readout of the results, has a high signal to noise background ratio, are easy to use, can be modified for automation and miniaturization, and provide verification that a compound specifically modulates TRPM5.
1. A high throughput screening assay for identifying TRPM5 ion channel specific enhancers comprising:
(a) determining an optimal and suboptimal concentration of an agent that increases intracellular calcium concentration in a cell, wherein the optimal concentration fully activates and the suboptimal concentration does not fully activate the TRPM5 ion channel;
(b) contacting a cell expressing TRPM5 with a suboptimal concentration of an agent that increases intracellular calcium concentration, wherein the cell has been preloaded with a membrane potential fluorescent dye;
(c) contacting the cell in step (b) with a potential enhancing compound;
(d) using an optical detector, measuring the fluorescent intensity of the cell in step (b) in the presence of said potential enhancing compound; and
(e) comparing the measured fluorescent intensity in step (d) to the fluorescent intensity of a different cell expressing TRPM5 in the presence of an optimal concentration of the agent from step (a), wherein a TRPM5 enhancer is a compound that increases TRPM5 activity in the cell in the presence of the suboptimal concentration of step (b).
2. The assay of claim 1 , further comprising selecting one or more test compounds that enhance TRPM5 activity.
3. The assay of claim 1 , wherein said cells are located in a multi-well vessel.
4. The assay of claim 3 , wherein said multi-well vessel comprises up to 96 wells.
5. The assay of claim 3 , wherein said multi-well vessel comprises greater than 96 wells.
6. The assay of claim 3 , wherein said multi-well vessel comprises 384 wells.
7. The assay of claim 3 , wherein said multi-well vessel comprises 1536 wells.
8. The assay of claim 1 , wherein said agent that increases calcium concentration is selected from the group consisting of: thrombin, adenosine triphosphate (ATP), carbachol, calcium ionophores, and agonists of endogenous G protein coupled receptor molecules.
9. The assay of claim 8 , wherein said agent is thrombin.
10. The assay of claim 8 , wherein said agent is ATP.
11. The assay of claim 8 , wherein said agent is carbachol.
12. The assay of claim 1 , wherein said membrane potential fluorescent dye is a Fluorescent Imaging Plate Reader Membrane Potential (FMP) dye.
13. The assay of claim 1 , wherein said optical detector is selected from the group consisting of: Fluorescent Imaging Plate Reader, FLEXStation, Voltage/Ion Probe Reader (VIPR), fluorescent microscope and charge-coupled device (CCD) camera, and Pathway HT.
14. The assay of claim 13 , wherein said optical detector is a Fluorescent Imaging Plate Reader.
15. The assay of claim 1 , wherein a TRPM5 specific enhancer increases TRPM5 activity relative to the activity of the TRPM5 ion channel in the presence of a suboptimal dose of the agent that increases intracellular calcium concentration.
16. The assay of claim 1 , wherein said optical and suboptimal concentration in step (a) are determined experimentally.
17. The assay of claim 1 , wherein the cell in step (a) is from the same population of cell from those in step (b).